Home › Compare › KKRAF vs ABBV
KKRAF yields 1.81% · ABBV yields 3.06%● Live data
📍 KKRAF pulled ahead of the other in Year 4
Combined, KKRAF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of KKRAF + ABBV for your $10,000?
Katakura Industries Co.,Ltd. engages in the textile, pharmaceutical, machinery, real estate, and life solutions businesses in Japan. The company manufactures and sells undergarments, hosiery products, aprons, and relaxing garments, as well as various functional fibers, such as the water-soluble fiber solvron and the thermal resistant NITIVY ALF. It also engages in the manufacture and sale of pharmaceuticals for treating cardiovascular illnesses comprising Frandol for the treatment of angina pectoris; and Frandol Tape, a heart medicine. In addition, the company manufactures and sells environment-related equipment (washers) and cutting oilrelated products, fire engines and firefighting-related equipment, and agricultural machinery, as well as car parts. Further, it provides commercial facility management services; and leases and develops various real estate lands. Additionally, the company offers agriculture-related products, food products, nursing care equipment, and general building maintenance and flower/tree planting services, as well as operates plant and pet specialty shops. The company was formerly known as Katakura Silk Spinning Co., Ltd. and changed its name to Katakura Industries Co.,Ltd. in November 1943. Katakura Industries Co.,Ltd. was founded in 1873 and is headquartered in Tokyo, Japan.
Full KKRAF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.